Filing Analysis
Interpace Biosciences, Inc. held its 2024 annual meeting of stockholders on November 12, 2024. The primary outcome was the ratification of EisnerAmper, LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
📋 Key Facts
- Annual meeting held on November 12, 2024.
- Stockholders ratified the appointment of EisnerAmper, LLP as independent auditors for FY2024.
- Voting results: 10,973,903 For; 13,711 Against; 2,680 Abstain.
Interpace Biosciences, Inc. filed an 8-K to announce its third quarter 2024 financial results for the period ended September 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly results (Item 2.02).
- Results cover the third quarter ended September 30, 2024.
- The press release containing the detailed financial data was issued on November 4, 2024.
Interpace Biosciences completed an exchange of all outstanding Series B Preferred Stock for newly created Series C Preferred Stock. This restructuring significantly reduces investor liquidation preferences and removes several restrictive protective provisions, but results in a massive potential dilution to common shareholders.
🚩 Red Flags
- Massive potential dilution: Conversion of Series C could result in over 23 million new common shares being issued.
- No cash inflow: The restructuring was a non-cash exchange that does not provide immediate working capital to the company.
- Significant change in capital structure via unregistered sale of equity securities.
📋 Key Facts
- Exchanged 47,000 shares of Series B Preferred Stock for 47,000 shares of Series C Preferred Stock.
- Series C Conversion Price is $2.02 per share (based on Oct 10, 2024 closing price).
- The aggregate number of Common Stock shares issuable upon conversion of all Series C shares is 23,267,326 shares.
- Series C Preferred Stock has no liquidation preference over Common Stock and no director designation rights.
- Termination of a prior Support Agreement with 1315 Capital as part of the exchange.
- The transaction resulted in zero cash proceeds for the Company.
Interpace Biosciences, Inc. filed an 8-K to announce its results of operations and financial condition for the second quarter ended June 30, 2024.
📋 Key Facts
- Report date: August 1, 2024
- Reporting period: Second Quarter ended June 30, 2024
- The filing serves to furnish quarterly financial results via a press release (Exhibit 99.1).
Interpace Biosciences, Inc. filed an 8-K to announce its results of operations and financial condition for the quarter ended March 31, 2024.
📋 Key Facts
- The filing relates to the quarterly earnings release for the period ending March 31, 2024.
- The report was filed on May 9, 2024.
- The company issued a press release (Exhibit 99.1) containing the financial results.
Interpace Biosciences, Inc. issued a press release announcing preliminary results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: March 7, 2024
- Reporting period: Q4 and Fiscal Year ended December 31, 2023
- The filing is a standard announcement of preliminary financial results via Exhibit 99.1.